EAM
ACHL

EdenTree Asset Management’s Achilles Therapeutics ACHL Stock Holding History

EdenTree Asset Management’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-100,000
Closed -$94.5K – 77
2023
Q2 		$94.5K Buy
+100,000
New +$95K 0.03% 74

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FA
Forefront Analytics West Conshohocken, Pennsylvania $110M AUM 18.54% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EdenTree Asset Management's ACHL Position: Q3 2023 in Review

EdenTree Asset Management sold out of Achilles Therapeutics (ACHL) in Q3 2023, closing a stake of 100,000 shares — an estimated $94.5K sold.

EdenTree Asset Management first reported a position in ACHL in Q2 2023 and held it in 1 quarter. The position peaked at $94.5K in Q2 2023. 18 funds tracked by Wall St. Rank hold ACHL as of Q3 2023.

  • EdenTree Asset Management reported no remaining Achilles Therapeutics position as of Q3 2023 after selling out during the quarter.
  • EdenTree Asset Management sold 100,000 Achilles Therapeutics shares in Q3 2023, an estimated $94.5K.
  • EdenTree Asset Management first reported a position in Achilles Therapeutics in Q2 2023 and held it in 1 quarter.
  • EdenTree Asset Management's Achilles Therapeutics position peaked at $94.5K in Q2 2023.
  • 18 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q3 2023.

Based on EdenTree Asset Management's 13F filing for Q3 2023, filed 14 Nov 2023.